Common use of Termination Prior to First Commercial Sale of the POI Product Clause in Contracts

Termination Prior to First Commercial Sale of the POI Product. In the event that the First Commercial Sale of the POI Product in the United States does not occur on or before December 31, 2005, GSK shall have the right to terminate the Agreement with respect to the OBD Chronic Product in (a) the United States and the ROW, (b) the United States, (c) both the United States and the Major Region of Europe, or (d) one or all of the Major Regions other than Europe; provided that if GSK terminates the Major Region of Japan it must also terminate the Major Region of Asia-Pacific. For the avoidance of doubt, in the event that GSK exercises its termination right pursuant to this Section 16.6.3, GSK shall retain all of its rights to the Adolor Products and the GI Products other than the OBD Chronic Product, and remain subject to its obligations, under this Agreement.

Termination Prior to First Commercial Sale of the POI Product. In the event that the First Commercial Sale of the POI Product in the United States does not occur on or before December 31, 2005, GSK shall have the right to terminate the Agreement with respect to the OBD Chronic Product all Adolor Products in (a) the United States and the ROWStates, (b) the United States, (c) both the United States and the Major Region of Europe, or (dc) one or all of the Major Regions other than the Major Region of Europe; provided that if GSK terminates the Major Region of Japan it must also terminate the Major Region of Asia-Pacific, or (d) the United States and the ROW. For the avoidance of doubt, in the event that GSK exercises its termination right pursuant to this Section 16.6.316.5.3, GSK shall retain all of its rights to the Adolor Products and the GI Products other than the OBD Chronic ProductProducts, and remain subject to its obligations, under this Agreement.

Termination Prior to First Commercial Sale of the POI Product. In the event that the First Commercial Sale of the POI Product in the United States does not occur on or before December 31, 2005**, GSK shall have the right to terminate the Agreement with respect to the OBD Chronic Product ** in (a) the United States and the ROW, (b) the United States, (c) both the United States and the Major Region of Europe, or (d) one or all of the Major Regions other than Europe; provided that if GSK terminates the Major Region of Japan it must also terminate the Major Region of Asia-Pacific. For the avoidance of doubt, in the event that GSK exercises its termination right pursuant to this Section 16.6.3, GSK shall retain all of its rights to the Adolor Products and the GI Products other than the OBD Chronic Product**, and remain subject to its obligations, under this Agreement.